Japanese COPD alliance with Novartis marks new ground for Eisai
This article was originally published in Scrip
Executive Summary
Eisai is moving into the respiratory disease sector in Japan through a co-promotion deal for three Novartis drugs for chronic obstructive pulmonary disease (COPD), including the inhaled beta-2 adrenoceptor agonist Onbrez (indacaterol).